Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0852 • ACR Convergence 2023
Screening for Specific Antinuclear Antibodies Using an Artificial Intelligence-enabled Antinuclear Antibody HEp-2 Substrate by Indirect Immunofluorescence Assay
Patrick Vanderboom, Surendra Dasari, Anne Tebo, Melissa Snyder and Ali Duarte-Garcia, Mayo Clinic, Rochester, MN
Background/Purpose: Antinuclear antibodies (ANA) are key biomarkers in the diagnostic evaluation of systemic autoimmune diseases and are widely used in clinical practice. The most accepted…
Abstract Number: 1181 • ACR Convergence 2023
Real-World Myositis Antibody Frequency and Patient Awareness
Raisa Lomanto Silva¹, shiri keret², Akanksha Sharma³, Tanya Chandra⁴, Siamak Moghadam-Kia¹, Chester V. Oddis⁵ and Rohit Aggarwal⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Bnai Zion, Atlit, Israel, ³UPMC Mercy Hospital, Pittsburgh, PA, ⁴Georgetown University Hospital, Washington, DC, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis-specific antibodies (MSA) represent unique phenotypes in idiopathic inflammatory myopathies (IIM). Myositis-associated antibodies (MAA) most commonly occur in IIM overlap syndromes. MSA and MAA…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 2266 • ACR Convergence 2023
Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception
May Choi¹, Karen Costenbader², Marvin Fritzler¹, Yvan St. Pierre³, Murray Urowitz⁴, John G. Hanly⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky³, Daniel Wallace¹⁰, David Isenberg¹¹, Anisur Rahman¹², Joan Merrill¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Ian Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jonsen²², Graciela S Alarcón²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan MacKay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane L. Kamen³², Anca Askanase³³, Jill Buyon³⁴ and Ann Clarke³⁵, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²²Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²³Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, ²⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, Barakaldo, Spain, ²⁷Emory University, Atlanta, GA, ²⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²⁹University of California San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴NYU Grossman School of Medicine, New York, NY, ³⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Using machine learning, we identified 4 patient clusters based on longitudinal autoantibody profiles in an international SLE inception cohort, which were predictive of disease…
Abstract Number: 0018 • ACR Convergence 2023
Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies
Rayan Najjar¹, Iago Pinal-Fernandez², Andrew Mammen³ and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²National Institutes of Health, Bethesda, MD, ³NIH, Bethesda, MD
Background/Purpose: Alternative splicing of mRNA results in important biological impacts with increasing evidence implicating it in the pathology of autoimmune diseases. However, it is understudied…
Abstract Number: 0561 • ACR Convergence 2023
Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry
Lucia Margarita Mendoza Martinez¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Maria Alejandra Medina¹, Silvia Papasidero¹, José caracciolo¹, Rosana Quintana², Lucila Garcia², Carla Andrea Gobbi², Sandy Sapag Durán², Alberto Spindler², Analia Patricia Alvarez², Cecilia Pisoni², Catalina Gomez², Raúl Hector Paniego², María Julia Santa cruz², Luciana Gonzalez Lucero², Rodrigo Aguila Maldonado², Sergio Gordon², Julia Romero², Gretel Rausch², Alberto Allievi², Alberto Omar Orden², johana zacariaz hereter³, Roberto Baéz², Andrea Vanesa González², Juan Manuel Vandale², Mario Alberto Goñi², Victor Caputo⁴, María Silvia Larroudé², Graciela Gómez², Josefina Marin², Victoria Collado², Gazzoni María Victoria², Marcos David Zelaya², Mónica Sacnún², Romina Rojas Tessel², Maira Alejandra Arias Saavedra², Maximiliano Machado Escobar², Pablo Astesana², Ursula Vanesa Paris², Bernando A. Pons-Estel² and Mercedes García⁵, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Militar Central, Buenos Aires, Argentina, ⁵Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina
Background/Purpose: Anti-Ro antibodies can be detected in 40% of patients with systemic lupus erythematosus (SLE) and have been associated with various clinical manifestations of the…
Abstract Number: 0906 • ACR Convergence 2023
Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients
Enrico Fuzzi¹, Anna Svanqvist², Christine Westerberg², Agneta Zickert³, Iva Gunnarsson⁴, Johan Rönnelid² and Elisabet Svenungsson⁵, ¹Karolinska University Hospital, Stockholm, Sweden, ²Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, Stocksund, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease where autoantibody production and immune complex (IC) formation play a key role. Which antibodies contribute…
Abstract Number: 1225 • ACR Convergence 2023
Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients
Yazmin Espinosa¹, Sara Concha¹, Clara Schulze¹ and Antonia Valenzuela², ¹Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ²Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Nailfold video capillaroscopy (NVC) is useful in diagnosing secondary Raynaud's phenomenon (RP) and predicting systemic sclerosis (SSc) and other CTD in adults. Recent studies…
Abstract Number: 1751 • ACR Convergence 2023
Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
Namit Kumar¹, Xueer Chen², Mary Ann Aure³, Andy Ishii⁴, Laura Martinez-Prat⁵, chelsea Bentow⁴, Jasmine Saini², Michael Mahler⁴ and Laurence Menard², ¹Bristol Myers Squibb, San Diego, CA, ²Bristol Myers Squibb, Princeton, NJ, ³Werfen, Chula Vista, CA, ⁴Werfen, San Diego, CA, ⁵Werfen Autoimmunity, Sant Cugat del Vallès, Spain
Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
Abstract Number: 0034 • ACR Convergence 2023
Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank
Jing Cui¹, Jeong Yee², Liming Liang³, Jack Ellrodt², Emily G. Oakes², Hongshu Guan² and Karen Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Antinuclear antibodies (ANA) to intranuclear particles are found in the blood of people with and without autoimmune diseases. To our knowledge, only 1 past…
Abstract Number: 0571 • ACR Convergence 2023
A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test
Gul Karakoc¹, Ge Liu¹, Jacy Zanussi², Cecilia Chung², Jorge Gamboa¹, Jonathan Mosley¹, Nancy Cox¹, C. Michael Stein¹ and Vivian Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Miami, Miami, FL
Background/Purpose: A positive ANA (ANA-POS) test is present in almost all patients with SLE and is also frequently present in other autoimmune (AI) diseases and…
Abstract Number: 0907 • ACR Convergence 2023
Epstein Barr Virus Reactivation May Associate with Transition from Incomplete to Systemic Lupus Erythematosus
Benjamin Jones¹, Carla Guthridge¹, Marci Beel¹, Catriona Wagner², Stan Kamp¹, Cristina Arriens³, Joan Merrill¹, Teresa Aberle¹, Nancy Redinger¹, Rebecca Wood⁴, Lauren Guthridge¹, Susan Macwana¹, Wade DeJager¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Patients with incomplete lupus erythematosus (ILE) have evidence of SLE but do not fulfill SLE classification criteria. Although most ILE patients maintain a relatively…
Abstract Number: 1269 • ACR Convergence 2023
The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes
Gregory McDermott¹, Keigo Hayashi¹, Pierre-Antoine Juge², Ritu Gill¹, Suzanne Byrne¹, Staci Gagne¹, Kathleen Vanni¹, Emily Kowalski¹, Grace Qian¹, Katarina Bade³, Alene Saavedra¹, Yumeko Kawano¹, Michael Diiorio³, Taylor Wolfgang¹, Edy Kim¹, Paul Dellaripa³, Michael Weinblatt⁴, Nancy Shadick³, Tracy J. Doyle¹ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
Abstract Number: 1758 • ACR Convergence 2023
Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Vijay Joshua², Monika Hansson³, Ronald Sjöberg⁴, Elisa Pin⁴, Cristina Ruiz-Romero⁵, Peter Nilsson⁴, Lars Klareskog² and Francisco J. Blanco⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, ²Karolinska Institutet, Stockholm, Sweden, ³Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, ⁴Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁵1) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, ⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…

« Previous Page
1
…
8
9
10
11
12
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].